Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia. A randomized controlled trial

JAMA

Volumn 281, Issue 2, 1999, Pages 137-144

  Stein, Evan A ^a   Illingworth, D Roger ^b   Kwiterovich, Peter O ^b   Liacouras, Chris A ^b   Siimes, Martti A ^b   Jacobson, Marc S ^b   Brewster, Thomas G ^b   Hopkins, Paul ^b   Davidson, Michael ^b   Graham, Kevin ^b   Arensman, Frederick ^b   Knopp, Robert H ^b   DuJovne, Carlos ^b   Williams, Christine L ^b   Isaacsohn, Jonathan L ^b   Jacobsen, Carol A ^b   Laskarzewski, Peter M ^b   Ames, Sharon ^b   Gormley, Glenn J ^b  

^a Metab and Atherosclerosis Res Ctr   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MEVINOLIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; ONSET AGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL MATURATION; TESTIS SIZE; TREATMENT OUTCOME;

EID: 0033550478     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.2.137     Document Type: Article

References (50)

1. Muller C. Angina pectoris in hereditary xanthomatosis. Arch Intern Med. 1939;64:675-700.
2. Brown MS, Goldstein JL. A receptor mediated pathway for cholesterol homeostasis. Science. 1986;232: 34-47.
3. Slack J. Risks of ischaemic heart disease in familial hyperlipoproteinemic states. Lancet. 1969;2:1380-1382.
4. Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation. 1974;49:476-488
5. Sugrue DD, Thompson GR, Oakley CM, Trayner IM, Steiner RE. Contrasting patterns of coronary atherosclerosis in normocholesterolaemic smokers and patients with familial hypercholesterolaemia. BMJ. 1981; 283:1358-1360.
6. Stein EA, Shapero J, McNerney C. Changes in plasma lipid and lipoprotein fractions after alteration in dietary cholesterol polyunsaturated, saturated, and total fat in free living normal and hypercholesterolemic children. Am J Clin Nutr. 1982;35:1375-1390.
7. Lauer RM, Obarzanek E, Kwiterovich PO Jr, et al. Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol. JAMA. 1995;273:1429-1435.
8. National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Bethesda, Md: National Heart, Lung, and Blood Institute; 1991. NIH publication 91-2732.
9. West RJ, Lloyd JK, Leonard JV. Long-term follow-up of children with familial hypercholesterolemia tested with cholestyramine. Lancet. 1980;2:873-875.
10. Groot PH, Dijkuis-Stoffelsma ER, Grose WFA, Anbagtsheer JJ, Fernandes J. The effects of colestipol hydrochloride on serum lipoprotein, lipid and lipoprotein B and A-I concentrations in children heterozygous for familial hypercholesterolemia. Acta Paediatr Scand. 1983;72:81-85.
11. Havel RJ, Hunninghake DB, Illingworth DR, et al. Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia: a multi-center study. Ann Intern Med. 1987;107:609-615.
12. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
13. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol-lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet. 1994;344:1383-1389.
14. Stein EA. Treatment of familial hypercholesterolemia with drugs in children. Arteriosclerosis. 1989;9 (suppl 1):145-151.
15. Ducobu J, Brasseur D, Chaudron JM, et al. Simvastatin use in children. Lancet. 1992;339:1488-1491.
16. Knipscheer HC, Boelen CCA, Kastelein JJP, et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res. 1996;39(suppl 5):867-871.
17. Lambert M, Lupien PJ, Gagne C, et al, for the Canadian Lovastatin in Children Study Group. Treatment of familial hypercholesterolemia in children and adolescents: effects of lovastatin. Pediatrics. 1996; 97:619-628.
18. Weidman W, Kwiterovich PO Jr, Jesse MJ, Nugent E. AHA committee report: diet in the healthy child. Circulation. 1983;67:1411A-1414A.
19. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970; 45:13-23.
20. Steiner PM, Freidel J, Brenner WF, Stein EA. Standardization of micromethodsfor plasma cholesterol, triglyceride, and HDL-cholesterol with the lipid clinics' methodology [abstract]. J Clin Chem. 1981;19:850.
21. Myers GL, Cooper CR, Winn CL, Smith SJ. The Centers for Disease Control - National Heart, Lung, and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements. Clin Lab Med. 1989;9:105-135.
22. Warnick GR, Albers JJ. A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high-density lipoprotein cholesterol. J Lipid Res. 1978;19:65-76.
23. Stein EA, Kreisberg R, Miller V, et al. Effect of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Arch Intern Med. 1990;150:341-345.
24. Stein EA, DiPersio L, Pesce AJ, et al. Enzyme-linked immunoabsorbent assay of apolipoprotein A-II in plasma using a monoclonal antibody. Clin Chem. 1986;32:967-971.
25. Stein EA, Kumbla L, Miller J, Srivastiva L, Kashyap ML. Development and evaluation of a competitive ELISA for Lp(a). Clin Chem. 1992;38:1067.
26. Kaplan LA, Miller JA, Stein EA. Simultaneous measurement of serum retinol, tocopherols, carotenes and carotenoids by high pressure liquid chromatography. J Clin Lab Anal. 1987;1:147-152.
27. Hollander M, Wolfe DA. Nonparametric Statistical Methods. New York, NY: John Wiley & Sons Inc; 1973.
28. 2 tests. Biometrics. 1954;10:417-451.
29. Mehta CR, Patel NR. A network algorithm for performing Fisher's exact test in r × c contingency tables: J Am Stat Assoc. 1983;78:427-434.
30. Lipid Research Clinics Program Epidemiology Committee. Plasmalipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation. 1979;60:427-439.
31. Donahue RP, Orchard TJ, Stein EA, Kuller LH. Apolipoproteins A-I, A-II, and B in young adults: associations with CHD risk factors. J Chronic Dis. 1986;39:823-830.
32. Tonstad S, Knudtzon J, Siversten M, Refsum H, Ose L. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr. 1996;129:42-49.
33. Colletti RB, Neufeld EJ, Roff NK, McAuliffe TL, Baker AL, Newburger JW: Niacin treatment of hypercholesterolemia in children. Pediatrics. 1993;92:78-82.
34. Steinmetz J, Morin C, Panek E, Siest G, Drouin P. Biological variations in hyperlipidemic children and adolescents treated with fenofibrate. Clin Chem Acta. 1981;112:43-53.
35. Wheeler KAH, West RJ, Lloyd JK, Barley J. Double-blind trial of bezafibrate in familial hypercholesterolemia. Arch Dis Child. 1985;60:34-37.
36. Schaefer EJ. Letter to the editor. N Engl J Med. 1988;319:1222.
37. Black DM, Lamkin G, Olivera EH, Laskarzewski PM, Stein EA. Sleep disturbance and HMG CoA reductase inhibitors [letter]. JAMA. 1990;264:1105.
38. Kostis JB, Rosen RC, Wilson AC. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. J Clin Pharmacol. 1994;34:989-996.
39. Muldoon MF, Ryan CM, Flory JD, Mathews KA, Manuck SB. Effects of cholesterol reduction on cognitive performance [abstract]. Circulation. 1997;96: 1-66. Abstract 360.
40. Gengo F, Cwudzinski D, Kinkel P, Block G, Stauffer L, Lines C. Effects of treatment with lovastatin and pravastatin on daytime cognitive performance. Clin Cardiol. 1995;18:209-214.
41. Harrison RW, Ashton CH. Do cholesterol-lowering agents affect brain activity? a comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clin Pharmacol. 1994;37:231-236.
42. Cutler N, Sramek J, Veroff A, Block G, Stauffer L, Lines C. Effects of treatmentwith simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia. Br J Clin Pharmacol. 1995;39:333-336.
43. McCormick DB, Greene HL. Vitamins. In: Burtis CA, Ashwood ER, eds. Tietz Textbook of Clinical Chemistry. Philadelphia, Pa: WB Saunders Co; 1994: 1275-1316.
44. Whitehead TP, Robinson D, Hale AC, Bailey AR Clinical Chemistry and Hematology: Adult Reference Values: BUPA Medical Research and Development. London, England: Battle Bridge House; 1994.
45. Kincaid HL. Clinical enzymology in pediatrics. In: Hicks JM, Boeckx RL, eds. Pediatrics Clinical Chemistry. Philadelphia, Pa: WB Saunders Co; 1984:349-402.
46. Kane JP, Malloy J, Ports TA, Phillips NR, Diehl CJ, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007-3012.
47. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
48. Stein E, Davidson M, Dobs A, et al. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. Am J Cardiol. 1998;82:311-316.
49. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81:582-587
50. Schrott HG, Stein EA, DuJovne CA, et al. Enhanced low-density lipoprotein cholesterol reduction and cost effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol. 1995;75:34-39.